incb-9471
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00393120)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- C-C chemokine receptor type 5ANTAGONIST
CCR5 antagonist
HIV-1 entry inhibitor, noncompetitive CCR5 allosteric antagonist. Indication: HIV infections
Chemistry & pharmacology
Loading structure…
SMILES
CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C- Mol. weight
- 559.68 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1688243 ↗
Also known as
- 5-((4-(4-(2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl)-3-methylpiperazin-1-yl)-4-methylpiperidin-1-yl)carbonyl)-4,6-dimethylpyrimidine
- 5-((4-(4-(2-ethoxy-5-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl)-3-methylpiperazin-1-yl)-4-methylpiperidin-1-yl)carbonyl)-4,6-dimethylpyrimidine dihydrochloride
- incb009471
- incb009471
- incb9471
- incb 9471
- incb-9471
- incb-9471
- incb-9471
- incb-9471
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00393120 | Phase 2 | Oct 1, 2006 | Incyte |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1